Codexis, a leading developer of biocatalysts for chemistry-based manufacturing applications in the pharmaceutical and biofuel industries, filed with the SEC for an IPO on Monday. The company booked $25 million in revenue in 2007 and plans to file for listing on the NASDAQ under the ticker CDXS. Credit Suisse and Goldman Sachs are the lead underwriters on the deal. No terms were disclosed in the initial filing.
